

#### **CONTACT:**

U.S. Physical Therapy, Inc.
Carey Hendrickson, Chief Financial Officer email: chendrickson@usph.com
Chris Reading, Chief Executive Officer
(713) 297-7000
Three Part Advisors
Joe Noyons
(817) 778-8424

## U.S. Physical Therapy Reports First Quarter 2022 Results

## **Declares Quarterly Dividend**

**Houston, TX, May 5, 2022** – U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention ("IIP") services, today reported results for the first quarter ended March 31, 2022 ("2022 First Quarter").

#### HIGHLIGHTS

- Operating Results per diluted share, a non-GAAP measure (defined below), was \$0.65 per diluted share for the 2022 First Quarter as compared to \$0.64 for the three months ended March 31, 2021 ("2021 First Quarter").
- For the 2022 First Quarter, USPH's net income attributable to its shareholders, a Generally Accepted Accounting Principles ("GAAP") measure, was \$8.8 million compared to \$8.2 million for the 2021 First Quarter. GAAP requires the Company to include a charge for the revaluation of its non-controlling interest, net of taxes, in its computation of earnings per diluted share. Earnings per diluted share on a GAAP basis, was \$0.67 for the 2022 First Quarter as compared to \$0.21 for the 2021 First Quarter.
- Adjusted EBITDA, a non-GAAP measure (defined below), was \$17.9 million for the 2022 First Quarter, a 14.2% increase from \$15.6 million for the 2021 First Quarter. See pages 10 through 11 for a discussion and reconciliation to results according to GAAP.
- Average visits per clinic per day in the 2022 First Quarter was 27.9, up from 27.1 in the 2021 First Quarter.
- Total patient visits were 1,063,519 for the 2022 First Quarter, an increase of 12.2% from 947,788 for the 2021 First Quarter. On a same store basis, visits increased 5.9% in the 2022 First Quarter as compared to the 2021 First Quarter.
- The net rate per patient visit was \$103.00 in the 2022 First Quarter as compared to \$104.72 in the 2021 First Quarter due to rate reductions implemented by Medicare in 2022.
- Net patient revenue from physical therapy operations was \$109.5 million for the 2022 First Quarter, an increase of 10.4% from \$99.3 million for the 2021 First Quarter.
- Industrial injury prevention ("IIP") services revenue was an all-time high of \$19.1 million for the 2022 First Quarter, representing a 90.5% increase over the 2021 First Quarter. Excluding \$6.8 million of revenue related to the November 2021 IIP acquisition, IIP services revenue increased 22.4% period over period.
- Total revenue of \$131.7 million for the 2022 First Quarter was 17.2% higher than total revenue of \$112.4 million for the 2021 First Quarter.
- Physical therapy operating costs were \$83.09 per visit in the 2022 First Quarter as compared to \$81.18 in the 2021 First Quarter, an increase of 2.4%. On a same store basis, physical therapy operating costs per visit increased 0.4% to \$81.08 in the 2022 First Quarter from \$80.78 in the 2021 First Quarter.
- Total operating cost was 79.8% of total revenue in the 2022 First Quarter, as compared to 77.0% for the 2021 First Quarter. Total salaries and related costs were 57.1% of total revenue for the 2022 First Quarter versus 56.8% for the 2021 First Quarter.

- On March 31, 2022, the Company acquired 70.0% of the equity interest in a six-clinic physical therapy practice in South Central Pennsylvania (Madden & Gilbert Physical Therapy, LLC). The business generates more than \$7.5 million in annual revenue and has approximately 71,000 patient visits per year.
- The Company's Board of Directors declared a quarterly dividend of \$0.41 per share payable on June 14, 2022 to shareholders of record on May 16, 2022.

#### SUMMARY OF FIRST QUARTER RESULTS

For the 2022 First Quarter, the Company's net income attributable to its shareholders was \$8.8 million as compared to \$8.2 million for the 2021 First Quarter. In accordance with GAAP, the revaluation of redeemable non-controlling interest, net of taxes, is not included in net income but charged directly to retained earnings; however, the charge for this change is included in the earnings per basic and diluted share calculation. Inclusive of the charge for revaluation of non-controlling interest, net of taxes, the amount is \$8.7 million, or \$0.67 per diluted share, for the 2022 First Quarter, and \$2.8 million, or \$0.21 per diluted share, for the 2021 First Quarter.

For the 2022 First Quarter, the Company's Operating Results, a non-GAAP measure, was \$8.4 million, or \$0.65 per diluted share, an increase of 2.2%, as compared to \$8.2 million, or \$0.64 per diluted share, for the 2021 First Quarter. See table on page 11.

#### First Quarter 2022 Compared to First Quarter 2021

• Reported total revenue for the 2022 First Quarter was \$131.7 million, an increase of 17.2% as compared to \$112.4 million for the 2021 First Quarter. See table below for a detail of reported total revenue (in thousands):

	Three Months Ended			Ended
	March 31, 2022		March 31, 2021	
Revenue related to Mature Clinics	\$	102,321	\$	98,649
Revenue related to 2022 Clinic Additions		195		-
Revenue related to 2021 Clinic Additions		6,823		149
Revenue from clinics sold or closed in 2022		199		190
Revenue from clinics sold or closed in 2021		-		266
Net patient revenue from physical therapy operations		109,538		99,254
Other revenue		872		546
Revenue from physical therapy operations		110,410		99,800
Revenue from management contracts		2,226		2,559
Revenue from industrial injury prevention services		19,068		10,009
Total Revenue	\$	131,704	\$	112,368

- Revenue from physical therapy operations increased \$10.6 million, or 10.6%, to \$110.4 million for the 2022 First Quarter from \$99.8 million for the 2021 First Quarter. Net patient revenue related to clinics opened or acquired prior to 2021 and still in operation at March 31, 2022 ("Mature Clinics") increased \$3.7 million, or 3.7%, to \$102.3 million for the 2022 First Quarter compared to \$98.6 million for the 2021 First Quarter.
- The average net patient revenue per visit was \$103.00 for the 2022 First Quarter as compared to \$104.72 for the 2021 First Quarter. Total patient visits increased 12.2% to 1,063,519 for the 2022 First Quarter from 947,788 for the 2021 First Quarter. Visits for Mature Clinics (same store) for the 2022 First Quarter increased 5.9% as compared to the 2021 First Quarter.
- Management contract revenue decreased 13.0% to \$2.2 million for the 2022 First Quarter as compared to \$2.6 million for the 2021 First Quarter.
- IIP services revenue increased 90.5% to \$19.1 million for the 2022 First Quarter as compared to \$10.0 million for the 2021 First Quarter. Excluding \$6.8 million of revenue related to the IIP acquisition in November 2021, IIP services revenue increased 22.4% in the 2022 First Quarter as compared to the 2021 First Quarter
- Total operating cost was \$105.1 million for the 2022 First Quarter, or 79.8% of total revenue, as compared to \$86.5 million, or 77.0% of total revenue, for the 2021 First Quarter. Operating cost related to Mature Clinics increased by \$4.8 million for the 2022 First Quarter compared to the 2021 First Quarter. On a per visit basis, operating cost related to Mature Clinics

increased 0.4% from \$80.78 in the 2021 First Quarter to \$81.08 in the 2022 First Quarter. In addition, operating cost related to the industrial injury prevention services business increased by \$7.6 million of which \$5.6 million related to the recent IIP acquisition. See table below for a detail of operating cost (in thousands):

	<b>Three Months Ended</b>			
	March 31, 2022		March 31, 2021	
Operating cost related to Mature Clinics	\$	81,034	\$	76,221
Operating cost related to 2022 Clinic Additions		840		-
Operating cost related to 2021 Clinic Additions		6,209		136
Operating cost related to clinics sold or closed in 2022		286		249
Operating cost related to clinics sold or closed in 2021		-		334
Operating cost related to physical therapy operations		88,369		76,940
Operating cost related to management contracts		1,831		2,245
Operating cost related to industrial injury prevention services		14,916		7,287
Total operating cost	\$	105,116	\$	86,472

- Total salaries and related costs, including all operations, were 57.1% of total revenue for the 2022 First Quarter versus 56.8% for the 2021 First Quarter. Rent, supplies, contract labor and other costs as a percentage of total revenue were 21.8% for the 2022 First Quarter versus 19.1% for the 2021 First Quarter. The provision for credit losses as a percentage of total revenue was 1.0% for 2022 First Quarter and 1.1% for 2021 First Quarter.
- Gross profit for the 2022 First Quarter, was \$26.6 million, an increase of \$0.7 million, or approximately 2.7%, as compared to \$25.9 million for the 2021 First Quarter. The gross profit percentage was 20.2% of total revenue for the 2022 First Quarter as compared to 23.0% for the 2021 First Quarter. The gross profit percentage for the Company's physical therapy operations was 20.0% for the 2022 First Quarter as compared to 22.9% for the 2021 First Quarter. The gross profit percentage on management contracts was 17.7% for the 2022 First Quarter as compared to 12.3% for the 2021 First Quarter. The gross profit percentage for the 2022 First Quarter as compared to 27.2% for the 2021 First Quarter. The table below details the gross profit (in thousands):

	Three Months Ended			
	March 31, 2022	March 31, 2021		
Physical therapy operations	\$ 22,041	\$ 22,860		
Management contracts	395	314		
Industrial injury prevention services	4,152	2,722		
Gross profit	\$ 26,588	\$ 25,896		

- Corporate office costs were \$11.6 million for the 2022 First Quarter compared to \$10.9 million for the 2021 First Quarter. Corporate office costs were 8.8% of total revenue for the 2022 First Quarter as compared to 9.7% for the 2021 First Quarter.
- Operating income for the 2022 First Quarter and 2021 First Quarter was \$15.0 million. Operating income as a percentage of total revenue was 11.4% for the 2022 First Quarter as compared to 13.4% for the 2021 First Quarter.
- The gain on revaluation of put-right liability was \$603,000. As part of the IIP business acquisition on November 30, 2021, the Company also agreed to the potential future purchase of a separate company under the same ownership that provides physical therapy and rehabilitation services to hospitals and other ancillary providers in a distinct market area. The owners have the right to put this transaction to the Company in approximately five years, with such right having a \$2.9 million value at March 31, 2022, as reflected on the Company's consolidated balance sheet in Other long-term liabilities. The value of this right will continue to be adjusted in future periods, as appropriate.
- The provision for income tax was \$3.5 million for the 2022 First Quarter and \$2.9 million for the 2021 First Quarter. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest (effective tax rate) was 28.6% for the 2022 First Quarter and 26.5% for the 2021 First Quarter. See table below (\$ in thousands):

<b>Three Months Ended</b>			Ended	
M	March 31, 2022		March 31, 2021	
\$	15,480	\$	14,830	
	,		,	
	(2.557)		(2,453)	
	(626)		(1,260)	
\$	(3,183)	\$	(3,713)	
\$	12,297	\$	11,117	
\$	3,498	\$	2,944	
	28.4%	, )	26.5%	
	М	March 31,         2022         \$ 15,480         (2,557)         (626)         \$ (3,183)         \$ 12,297         \$ 3,498	March 31, 2022       March 31, 2022         \$ 15,480       \$         (2,557)       (626)         \$ (3,183)       \$         \$ 12,297       \$	

• Net income attributable to redeemable non-controlling interest (temporary equity) was \$2.6 million for the 2022 First Quarter and \$2.5 million for the 2021 First Quarter. Net income attributable to non-controlling interest (permanent equity) was \$0.6 million for the 2022 First Quarter and \$1.3 million for the 2021 First Quarter.

#### **Other Financial Measures**

For the 2022 First Quarter, the Company's Adjusted EBITDA, a non-GAAP measure, was \$17.9 million, an increase of 14.2% from \$15.6 million in the 2021 First Quarter. See definition, explanation and calculation of Adjusted EBITDA, a non-GAAP measure, in the schedule on pages 10 through 11.

#### Medicare Accelerated and Advance Payment Program ("MAAPP Funds")

On March 27, 2020, in response to the COVID-19 pandemic, the federal government approved the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act provided waivers, reimbursement, grants and other funds to assist health care providers during the COVID-19 pandemic, including \$100.0 billion in appropriations for the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, to be used for preventing, preparing, and responding to the coronavirus, and for reimbursing eligible health care providers for lost revenues and health care related expenses that are attributable to COVID-19.

The CARES Act allowed for qualified healthcare providers to receive advanced payments under the MAAPP Funds during the COVID-19 pandemic. Under this program, healthcare providers could choose to receive advanced payments for future Medicare services provided. The Company applied for and received approval from Centers for Medicare & Medicaid Services ("CMS") in April 2020. The Company recorded the \$14.1 million in advance payments received as a liability. During the 2021 First Quarter, the Company repaid the MAAPP Funds of \$14.1 million rather than applying them to future services performed.

#### Acquisition in First Quarter 2022

On March 31, 2022, the Company acquired a 70% interest in a six-clinic physical therapy practice in South Central Pennsylvania – Madden and Gilbert Physical Therapy, LLC. The practice's owners retained 30% of the equity interests. The purchase price for the 70% equity interest was approximately \$11.5 million. The business generates more than \$7.5 million in annual revenue and has approximately 71,000 patient visits per year.

The Company's strategy is to continue acquiring multi-clinic outpatient physical therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships and to continue acquiring companies that provide industrial injury prevention services.

#### U.S. Physical Therapy Press Release May 5, 2022

#### **Quarterly Dividend**

The Board of Directors declared a quarterly dividend of \$0.41 per share payable on June 14, 2022, to shareholders of record on May 16, 2022.

#### **Management's Comments**

Chris Reading, Chief Executive Officer, said, "We finished the first quarter in strong fashion, despite a slow start, with visits heavily impacted by Omicron and our highest level ever of employee-related quarantines. I am very pleased with our same store volume numbers along with our cost management, with same store costs up only 0.4% on a per visit basis despite significant pricing pressure on labor and materials. We made a lot of progress in the quarter, and I am pleased with where we are as we enter a traditionally busy season for us. On the acquisition front, we expect to have another very productive year."

#### First Quarter 2022 Conference Call

U.S. Physical Therapy's management will host a conference call at 10:30 a.m. Eastern Time, 9:30 a.m. Central Time, on May 5, 2022, to discuss results for the Company's 2022 First Quarter. Interested parties may participate in the call by dialing 1-877-830-2598 or 785-424-1062 and entering reservation number USPHQ12022 approximately 10 minutes before the call is scheduled to begin. To listen to the live call via webcast, go to the Company's website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived and can be accessed until August 5, 2022, at U.S. Physical Therapy's website.

#### **Forward-Looking Statements**

This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as "believes", "expects", "intends", "plans", "appear", "should" and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

- the multiple effects of the impact of public health crises and epidemics/pandemics, such as the novel strain of COVID-19 and its variants, for which the total financial magnitude cannot be currently estimated;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
  the impact of COVID-19 related vaccination and/or testing mandates at the federal, state and/or local level, which could have an
- adverse impact on staffing, revenue, costs and the results of operations;
- changes as the result of government enacted national healthcare reform;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
- revenue and earnings expectations;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity and retaining key personnel;

# U.S. Physical Therapy Press Release May 5, 2022

• competitive environment in the industrial injury prevention services business, which could result in the termination or nonrenewal of contractual service arrangements and other adverse financial consequences for that service line;

• acquisitions, and the successful integration of the operations of the acquired businesses;

• impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);

• maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;

• a security breach of our or our third party vendors' information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;

• maintaining clients for which we perform management and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;

- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.

See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the "SEC") for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.

#### About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 601 outpatient physical therapy clinics in 39 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention services business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at <u>www.usph.com</u>. The information included on that website is not incorporated into this press release.

#### U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited)

	Three Months Ended			Ended
	March 31, 2022		March 31, 2021	
Net patient revenue Other revenue	\$	109,538 22,166	\$	99,254 <u>13,114</u>
Net revenue Operating cost:		131,704 75,149		112,368
Salaries and related costs Rent, supplies, contract labor and other Provision for credit losses		28,662 1,305		63,815 21,457 1,200
Total operating cost	_	105,116		86,472
Gross profit		26,588		25,896
Corporate office costs Operating income		<u>11,556</u> 15,032		<u>10,874</u> 15,022
Other income and expense		15,052		13,022
Equity in earnings of unconsolidated affiliate Interest and other income, net		339 46		- 54
Gain on revaluation of put-right liability Interest expense - debt and other		603 (540)		(246)
Total other income and expense	_	448	_	(192)
Income before taxes		15,480		14,830
Provision for income taxes		3,498		2,944
Net income		11,982		11,886
Less: net income attributable to non-controlling interest: Redeemable non-controlling interest - temporary equity Non-controlling interest - permanent equity		(2,557) (626) (3,183)		$(2,453) \\ (1,260) \\ (3,713)$
Net income attributable to USPH shareholders	\$	8,799	\$	8,173
Basic and diluted earnings per share attributable to USPH shareholders	\$	0.67	\$	0.21
Shares used in computation - basic and diluted		12,937		12,870
Dividends declared per common share	\$	0.41	\$	0.35

#### U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (IN THOUSANDS, EXCEPT PER SHARE DATA)

	Μ	arch 31, 2022		ecember 51, 2021
ASSETS	(u	naudited)		
Current assets:			+	
Cash and cash equivalents	\$	24,229	\$	28,567
Patient accounts receivable, less allowance for credit losses of \$2,799 and \$2,768, respectively		49,335		46,272
Accounts receivable - other		18,239		16,144
Other current assets		4,040		4,183
Total current assets		95,843		95,166
Fixed assets:		(0.205		50 742
Furniture and equipment		60,205		58,743
Leasehold improvements		40,541		39,194
Fixed assets, gross		100,746		97,937
Less accumulated depreciation and amortization		76,601		74,958
Fixed assets, net		24,145		22,979
Operating lease right-of-use assets		94,243		96,427
Investment in unconsolidated affiliate		12,422		12,215
Goodwill		443,692		434,679
Other identifiable intangible assets, net		91,546		86,382
Other assets	-	1,972	<u>_</u>	1,578
Total assets	\$	763,863	\$	749,426
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTEREST				
Current liabilities: Accounts payable - trade	\$	3,272	¢	3,268
Accounts payable - due to seller of acquired business	φ	3,203	Φ	3,208
Accounts payable - due to sener of acquired business Accrued expenses		51,121		45,705
Current portion of operating lease liabilities		30,625		30,475
Current portion of notes payable		799		830
Total current liabilities		89,020		83,481
Notes payable, net of current portion		4,128		3,587
Revolving line of credit		118,000		114,000
Deferred taxes		16,067		14,385
Operating lease liabilities, net of current portion		72,162		74,185
Other long-term liabilities		4,262		7,345
Total liabilities		303,639		296,983
Redeemable non-controlling interest - temporary equity Commitments and Contingencies		158,008		155,262
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity: Preferred stock, \$.01 par value, 500,000 shares authorized, no shares issued and outstanding Common stock, \$.01 par value, 20,000,000 shares authorized,		-		-
15,206,173 and 15,126,160 shares issued, respectively		151		151
Additional paid-in capital		105,205		102,688
Retained earnings		227,243		224,395
Treasury stock at cost, 2,214,737 shares		(31,628)		(31,628)
Total USPH shareholders' equity		300,971		295,606
Non-controlling interest - permanent equity		1,245		1,575
Total USPH shareholders' equity and non-controlling interest - permanent equity		302,216		297,181
Total liabilities, redeemable non-controlling interest, USPH shareholders' equity and non-controlling interest - permanent equity	\$	763,863	\$	749,426

(unaudited)				
	Three Months Ende			
	IVI	arch 31, 2022	IV	arch 31, 2021
OPERATING ACTIVITIES		2022		2021
Net income including non-controlling interest and earnings from				
unconsolidated affiliates, net	\$	11,982	\$	11,886
Adjustments to reconcile net income including non-controlling interest to net cash provided		,		,
by operating activities:				
Depreciation and amortization		3,824		2,681
Provision for credit losses		1,305		1,200
Equity-based awards compensation expense		1,846		1,651
Deferred income taxes		2,132		2,181
Gain on revaluation of put-right liability		(603)		-
Earnings in unconsolidated affiliate		(339)		-
Other		93		96
Changes in operating assets and liabilities:		(1 (7))		(4, 600)
Increase in patient accounts receivable		(4,676)		(4,688)
(Increase) decrease in accounts receivable - other		(2,145)		220
(Increase) decrease in other assets		(735)		221
Increase in accounts payable and accrued expenses		1,445		3,969
Decrease in other long-term liabilities		(2,480)		(1,743)
Net cash provided by operating activities INVESTING ACTIVITIES		11,649		17,674
Purchase of fixed assets		(2,528)		(1.609)
Purchase of majority interest in businesses, net of cash acquired		(2,328) (11,242)		(1,608) (11,747)
Purchase of redeemable non-controlling interest, temporary equity		(11,242) (2,211)		(11,/4/)
Purchase of non-controlling interest, permanent equity		(2,211) (99)		
Proceeds on sales of partnership interest, clinics and fixed assets		(99)		152
Distributions from unconsolidated affiliate		132		132
Sales of non-controlling interest-permanent		152		
Net cash used in investing activities		(15,944)		(13,203)
FINANCING ACTIVITIES		(15,54)		(15,205)
Distributions to non-controlling interest, permanent and temporary equity		(3,711)		(5,265)
Cash dividends paid to shareholders		-		(0,200)
Proceeds from revolving line of credit		35,000		60,000
Payments on revolving line of credit		(31,000)		(60,000)
Principal payments on notes payable		(332)		(145)
(Payment) receipt of Medicare Accelerated and Advance Funds		-		(14,054)
Other		-		12
Net cash used in financing activities		(43)		(19,452)
Net decrease in cash and cash equivalents		(4,338)		(14,981)
Cash and cash equivalents - beginning of period		28,567		32,918
Cash and cash equivalents - end of period	\$	24,229	\$	17,937
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION				
Cash paid during the period for:				
Income taxes	\$	81	\$	62
Interest paid	\$	525	\$	298
Non-cash investing and financing transactions during the period:				
Purchase of businesses - seller financing portion	\$	300	\$	300
Notes payable related to purchase of redeemable non-controlling interest, temporary equity	\$	246	\$	4,829
Notes payable due to purchase of non-controlling interest, permanent equity	\$	296	\$	-
Notes receivable related to sale of partnership interest - redeemable non-controlling interest	\$	-	\$	287
Dividends payable to USPH shareholders	\$	5,327	\$	4,514

#### U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES NON-GAAP MEASURES (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited)

The following tables provide detail of the diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results and Adjusted EBITDA. Management believes providing Operating Results and Adjusted EBITDA to investors is useful information for comparing the Company's period-to-period results.

Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders per the consolidated statements of income less the gain on the revaluation of the put-right liability. In accordance with GAAP, the revaluation of redeemable non-controlling interest, net of tax, is included in the earnings per basic and diluted share calculation, although it is not included in net income but charged directly to retained earnings.

Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, gain on revaluation of put-right liability and equity-based awards compensation expense. Management believes reporting Adjusted EBITDA is useful information for investors in comparing the Company's period-to-period results as well as comparing with similar businesses which report adjusted EBITDA as defined by their company.

Management uses Operating Results and Adjusted EBITDA, which eliminates certain items described above that can be subject to volatility and unusual costs, as one the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results and Adjusted EBITDA is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures.

Operating Results and Adjusted EBITDA are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.

#### U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES OPERATING RESULTS AND ADJUSTED EBITDA 2022 PERIODS COMPARED TO 2021 PERIODS (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited)

Computation of earnings per share - USPH shareholders: Net income attributable to USPH shareholders2022 2021Credit (charges) to retained earnings: Revaluation of redeemable non-controlling interest Tax effect at statutory rate (federal and state) of 25.55%(153) $(7,270)$ $\overline{3}$ (153) $(7,270)$ $\overline{3}$ Earnings per share (basic and diluted) $\underline{\$}$ $0.67$ $\underline{\$}$ $0.21$ Adjustments: Gain on revaluation of put-right liability Operating Results (a non-GAAP measure)(603) $\underline{\$}$ $-$ Basic and diluted Operating Results per share (a non-GAAP measure) $\underline{\$}$ $0.65$ $\underline{\$}$ $0.64$ Shares used in computation - basic and diluted $12,937$ $12,937$ $12,870$ Net income attributable to USPH shareholders $\$$ $\$$ $\$$ Adjustments: Depreciation and amortization Interest expense - debt and other Provision for income taxes $3,498$ $2,944$ $2,879$ $3,498$ $2,944$ $*$ Adjustments: Depreciation and anortization Interest expense - debt and other Provision for income taxes $3,498$ $2,944$ $3,498$ $2,944$ $2,641$ $1,544$ Adjusted EBITDA (a non-GAAP measure) $\underline{\$}$ $\underline{\$}$ $1.5642$ Adjusted EBITDA (a non-GAAP measure) $\underline{\$}$ $1.5642$		Three Months Er	nded March 31,
Net income attributable to USPH shareholders\$		2022	2021
Credit (charges) to retained earnings: Revaluation of redeemable non-controlling interest(153)(7,270)Tax effect at statutory rate (federal and state) of 25.55% $\underline{S}$ $\underline{8,685}$ $\underline{S}$ $\underline{2,2760}$ Earnings per share (basic and diluted) $\underline{S}$ $0.67$ $\underline{S}$ $0.21$ Adjustments: Gain on revaluation of put-right liability Tax effect at statutory rate (federal and state) $(603)$ $-$ Tax effect at statutory rate (federal and state) $115$ $(1,857)$ Operating Results (a non-GAAP measure) $\underline{S}$ $0.65$ $\underline{S}$ Basic and diluted Operating Results per share (a non-GAAP measure) $\underline{S}$ $0.65$ $\underline{S}$ Shares used in computation - basic and diluted $12,937$ $12,870$ Net income attributable to USPH shareholders $S$ $8,799$ $\underline{S}$ $8,173$ Adjustments: Depreciation and amortization Interest income $3,824$ $2,681$ $2022$ Adjustments: Depreciation and amortization Interest income $3,824$ $2,681$ Adjustments: Depreciation for income taxes $(46)$ $(54)$ $(603)$ $-$ Interest expense - debt and other Three Months Ender March 31, $(46)$ $(54)$ $(603)$ $-$ Interest income $540$ $247$ $2021$ Results of put-right liability $(603)$ $(603)$ $-$ Interest income Interest income $540$ $247$ Interest income $(46)$ $540$ $247$ Interest income Interest income $540$ $247$ <th></th> <th></th> <th></th>			
Revaluation of redeemable non-controlling interest(153)(7,270)Tax effect at statutory rate (federal and state) of 25.55% $39$ $1,857$ S8,685 $$2,760$ Earnings per share (basic and diluted) $$0.67$ $$0.21$ Adjustments: Gain on revaluation of put-right liability (federal and state)(603)-Tax effect at statutory rate (federal and state)1537,270Dependent of put-right liability (federal and state)(603)-Operating Results (a non-GAAP measure) $$8,350$ $$8,173$ Basic and diluted Operating Results per share (a non-GAAP measure) $$0.65$ $$0.64$ Shares used in computation - basic and diluted $12,937$ $12,870$ Three Months Ended March 31, 20222021Net income attributable to USPH shareholders $$8,8,799$ $$8,173$ Adjustments: Depreciation and amortization Interest income (640) $3,824$ $2,681$ Interest income (460)(64)(64)Gain on revaluation of put-right liability (fods)(603)-Interest spense - debt and other Provision for income taxes (24) $540$ $2474$ Provision for income taxes (540) $2,944$ $2,944$		\$ 8,799	\$ 8,173
Tax effect at statutory rate (federal and state) of 25.55% $39$ $1,857$ S8.685\$2.760Earnings per share (basic and diluted)S0.67\$Adjustments: Gain on revaluation of put-right liability Revaluation of redeemable non-controlling interest1537.270Tax effect at statutory rate (federal and state)115(1.857)Operating Results (a non-GAAP measure)\$8.350\$Basic and diluted Operating Results per share (a non-GAAP measure)\$0.65\$Shares used in computation - basic and diluted12.93712.870Net income attributable to USPH shareholders\$8,799\$8,173Adjustments: Depreciation and amortization Interest income Gain on revaluation of put-right liability (603)3,8242,681Interest expense - debt and other Provision for income taxes Equity-based awards compensation expense5,400247Provision for income taxes Equity-based awards compensation expense3,4982,944			
S8.685\$2.760Earnings per share (basic and diluted) $\underline{\$}$			
Earnings per share (basic and diluted)§0.67§0.21Adjustments: Gain on revaluation of put-right liability Revaluation of redeemable non-controlling interest Tax effect at statutory rate (federal and state)1537,270Tax effect at statutory rate (federal and state)115(1,857)Operating Results (a non-GAAP measure)§0.65§Basic and diluted Operating Results per share (a non-GAAP measure)§0.65§Shares used in computation - basic and diluted12,93712,870Three Months Ended March 31, 202220222021Net income attributable to USPH shareholders§8,799\$Adjustments: Depreciation and amortization Interest income Gain on revaluation of put-right liability (603)3,8242,681Of Gain on revaluation of put-right liability Interest expense - debt and other Provision for income taxes Same sea3,4982,944Equity-based awards compensation expense3,4982,944	Tax effect at statutory rate (federal and state) of 25.55%		1,857
Adjustments: Gain on revaluation of put-right liability(603)-Revaluation of redeemable non-controlling interest1537,270Tax effect at statutory rate (federal and state) $115$ $(1.857)$ Operating Results (a non-GAAP measure) $\underline{\$$ $\underline{\$$ $\underline{\$}$ Basic and diluted Operating Results per share (a non-GAAP measure) $\$$ $\underline{\$$ $\underline{\$$ Shares used in computation - basic and diluted $12,937$ $12,870$ Net income attributable to USPH shareholders $\$$ $\$$ $\$,739$ Adjustments: Depreciation and amortization Interest income $3,824$ $2,681$ Interest income Interest expense - debt and other Provision for income taxes $5,400$ $3,498$ $2,944$ Equity-based awards compensation expense $5,400$ $247$		\$ 8,685	\$ 2,760
Gain on revaluation of put-right liability(603)-Revaluation of redeemable non-controlling interest1537,270Tax effect at statutory rate (federal and state) $115$ $(1,857)$ Operating Results (a non-GAAP measure)§ $8,350$ §Basic and diluted Operating Results per share (a non-GAAP measure)§ $0.65$ §Shares used in computation - basic and diluted $12,937$ $12,870$ Net income attributable to USPH shareholders§ $8,799$ § $8,173$ Adjustments: Depreciation and amortization Interest income $3,824$ $2,681$ (46) $(54)$ (54)Interest income Provision for income taxes Equity-based awards compensation expense $540$ $247$	Earnings per share (basic and diluted)	\$ 0.67	\$ 0.21
Revaluation of redeemable non-controlling interest1537,270Tax effect at statutory rate (federal and state) $115$ $(1.857)$ Operating Results (a non-GAAP measure) $\$$ $\underline{\$$ $\underline{\$$ Basic and diluted Operating Results per share (a non-GAAP measure) $\underline{\$$ $\underline{\$$ $\underline{\$$ Shares used in computation - basic and diluted $12.937$ $12.870$ Three Months Ended March 31,20222021Net income attributable to USPH shareholders $\$$ $\$,799$ $\$$ Adjustments:Depreciation and amortization $3.824$ $2,681$ Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other $540$ $247$ Provision for income taxes $3.498$ $2.944$ Equity-based awards compensation expense $1.846$ $1.651$			
Tax effect at statutory rate (federal and state)115(1,857)Operating Results (a non-GAAP measure) $\underline{\$ \ 0.65}$ $\underline{\$ \ 0.65}$ $\underline{\$ \ 0.64}$ Basic and diluted Operating Results per share (a non-GAAP measure) $\underline{\$ \ 0.65}$ $\underline{\$ \ 0.64}$ Shares used in computation - basic and diluted $12,937$ $12,870$ Three Months Ended March 31,20222021Net income attributable to USPH shareholders $\$ \ 8,799$ $\$ \ 8,799$ $\$ \ 8,799$ $\$ \ 8,173$ Adjustments:Depreciation and amortization $3,824$ $2,681$ Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other $540$ 247Provision for income taxes $3,498$ $2,944$ Equity-based awards compensation expense $1,846$ $1,651$		(603)	-
Operating Results (a non-GAAP measure) $$$			
Basic and diluted Operating Results per share (a non-GAAP measure) $$ 0.65$ $$ 0.64$ Shares used in computation - basic and diluted $12,937$ $12,870$ Three Months Ended March 31, 20222021 $2022$ $2021$ Net income attributable to USPH shareholders $$ 8,799$ $$ 8,173$ Adjustments: Depreciation and amortization Interest income Gain on revaluation of put-right liability Interest expense - debt and other Provision for income taxes Equity-based awards compensation expense $$ 3,498$ $2,944$	- · · · · · · · · · · · · · · · · · · ·	115	(1,857)
Shares used in computation - basic and diluted       12,937       12,870         Three Months Ended March 31,       2022       2021         Net income attributable to USPH shareholders       \$ 8,799       \$ 8,173         Adjustments:       Depreciation and amortization       3,824       2,681         Interest income       (46)       (54)         Gain on revaluation of put-right liability       (603)       -         Interest expense - debt and other       540       247         Provision for income taxes       3,498       2,944         Equity-based awards compensation expense       1,846       1,651	Operating Results (a non-GAAP measure)	\$ 8,350	\$ 8,173
Three Months Ended March 31,20222021Net income attributable to USPH shareholders\$ 8,799\$ 8,173Adjustments: Depreciation and amortization Interest income Gain on revaluation of put-right liability Interest expense - debt and other Provision for income taxes Equity-based awards compensation expense3,824 (46) (54) (603) (46) (603)	Basic and diluted Operating Results per share (a non-GAAP measure)	\$ 0.65	\$ 0.64
20222021Net income attributable to USPH shareholders\$ 8,799\$ 8,173Adjustments: Depreciation and amortization3,8242,681Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651	Shares used in computation - basic and diluted	12,937	12,870
Net income attributable to USPH shareholders\$ 8,799\$ 8,173Adjustments: Depreciation and amortization3,8242,681Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651		Three Months Er	nded March 31,
Adjustments:3,8242,681Depreciation and amortization3,8242,681Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651		2022	2021
Depreciation and amortization3,8242,681Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651	Net income attributable to USPH shareholders	\$ 8,799	\$ 8,173
Interest income(46)(54)Gain on revaluation of put-right liability(603)-Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651			
Gain on revaluation of put-right liability(603)-Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651		3,824	2,681
Interest expense - debt and other540247Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651			(54)
Provision for income taxes3,4982,944Equity-based awards compensation expense1,8461,651			-
Equity-based awards compensation expense1,8461,651	•		
Adjusted EBITDA (a non-GAAP measure)         \$ 17,858         \$ 15,642			1,651
	Adjusted EBITDA (a non-GAAP measure)	<u>\$ 17,858</u>	\$ 15,642

### Page 12

## U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES RECAP OF PHYSICAL THERAPY OPERATIONS CLINIC COUNT

Date	Number of Clinics		
March 31, 2021	564		
June 30, 2021	575		
September 30, 2021	579		
December 31, 2021	591		
March 31, 2022	601		